Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
HIV Vaccine Vaccines historically have been the most effective means to prevent and even eradicate infectious diseases. They safely and cost-effectively prevent illness, disability and death. Like smallpox, measles, yellow fever and polio vaccines, a preventive HIV vaccine could help save millions of lives. Unfortunately, we do not have a vaccine for HIV. The virus has unique ways of evading the immune system; As a result, scientists do not have a clear picture of what is needed to provide against protection of HIV. HIV or the Human immunodeficiency virus occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. HIV is different from other viruses because your immune system never fully gets rid of it. Most people who are infected with a virus recover from the infection, and their immune systems clear the virus from their bodies. This is true even for viruses that can be deadly HIV is different from other viruses because your immune system never fully gets rid of it. Most people who are infected with a virus recover from the infection, and their immune systems clear the virus from their bodies. This is true even for viruses that can be deadly this then causes acquired immunodeficiency syndrome or AIDS acquired immunodeficiency syndrome or AIDS. However, there are reasons to be optimistic about the search for an HIV vaccine, despite the difficulties and the slow progress so far. Vaccines against other diseases took many decades to develop, and HIV was only discovered in the mid 1980’s. A little more than half of the world's population is infected with the virus. A larger number of AIDS deaths occur in Sub-Saharan Africa because of the lack of HIV information, causing economic problems and poverty. Treatment with antiretroviral drugs is helping to reduce the mortality and the morbidity of HIV infection nationwide. A lot of people do not develop any symptoms after being infected with the virus. Others develop flu like illness that can last up to several weeks after being exposed to the virus. They will usually complain of fever, headache, tiredness, and enlarged lymph glands in the neck. These symptoms will disappear on their own and following the initial infections you may have no symptoms. After being diagnosed with AIDS the survival is 2-3 years and people become more pronged to develop various types of cancers. Everyone who has tested positive for HIV must work with his or her doctor to figure out the best possible treatment. There is not a cure for HIV but there are medications to help treat the disease and prolong the life of the patient. Keep in mind that although someone is being treated for the infection, it can still be spread through the exchange of bodily fluids. HIV vaccine research has focused on many alternative vaccine strategies. It is imperative to note that a successful vaccine needs to elicit both B cell and T cell responses in order to be an effective preventive vaccine. Integrated research endeavors in designing and developing antigens that elicit broadly neutralizing antibody responses and protect against HIV infection, boosting up the T cell response to control viral replication and handling the problem of enormous HIV diversity are crucial elements in the pursuit of an HIV vaccine. Immune correlates of the modestly efficient RV144 trial have identified the V1V2 region to be the target of neutralizing antibodies and follow up studies are underway to evaluate multiple prime-boost regimens which will generate more data and insights in to the development of a vaccine. Recent discovery of bnAbs has provided a new and exciting avenue for designing an efficient vaccine. Unique approaches like B-cell lineage vaccine and AAV vector vaccines to elicit bnAb responses are being studied. By and large, this is a tremendously motivating period for HIV vaccine researchers, one that spawns more optimism markedly higher than in preceding years.For more
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
HIV Vaccine Vaccines historically have been the most effective means to prevent and even eradicate infectious diseases. They safely and cost-effectively prevent illness, disability and death. Like smallpox, measles, yellow fever and polio vaccines, a preventive HIV vaccine could help save millions of lives. Unfortunately, we do not have a vaccine for HIV. The virus has unique ways of evading the immune system; As a result, scientists do not have a clear picture of what is needed to provide against protection of HIV. HIV or the Human immunodeficiency virus occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. HIV is different from other viruses because your immune system never fully gets rid of it. Most people who are infected with a virus recover from the infection, and their immune systems clear the virus from their bodies. This is true even for viruses that can be deadly HIV is different from other viruses because your immune system never fully gets rid of it. Most people who are infected with a virus recover from the infection, and their immune systems clear the virus from their bodies. This is true even for viruses that can be deadly this then causes acquired immunodeficiency syndrome or AIDS acquired immunodeficiency syndrome or AIDS. However, there are reasons to be optimistic about the search for an HIV vaccine, despite the difficulties and the slow progress so far. Vaccines against other diseases took many decades to develop, and HIV was only discovered in the mid 1980’s. A little more than half of the world's population is infected with the virus. A larger number of AIDS deaths occur in Sub-Saharan Africa because of the lack of HIV information, causing economic problems and poverty.
Market analysis : In the past 5 years, Pfizer has delivered 25 million HIV vaccine doses to the U.S. government's stockpile to protect against renegade stocks or re-engineered viruses.. HIV is one of the most leading disease in the world. Global revenue for HIV vaccine was nearly $44.8 billion in 2011.This market is expected for HIV vaccine to increase from $74 .6 billion in 2020. In the case of USA $18.3billion in 2011, but it will increase half of the percentage by the end of 2017.
Upcoming conferences
Global Summit and Expo on Vaccines & Vaccination
Nov 30-Dec 02, 2015 San Francisco, USA
10th Euro Global Summit and Expo on Vaccines & Vaccination
June 16-18, 2016 Rome, Italy
11th Global Summit and Expo on Vaccines & Vaccination
Sept 12-14, 2016 Pheonix, USA
International Conference on Hepatitis Vaccines
Sept 26-28, 2016 Valencia, Spain
International Conferences on Tarvel Medicine and Vaccines
Aug 1-2, 2016 Seattle, USA
Children Vaccines World Congress
Oct 10-12, 2016 Kuala Lumpur, Malaysia
Annual Conference on Virulant HIV Vaccines
Oct 3-5, 2016 Miami, USA
12th Global Vaccines & Vaccination Summit and Expo
Oct 20-22, 2016 Dubai, UAE
5th International Conference and Exhibition on Immunology
Oct 24-26, 2016 Chicago, USA
International Conference on Cancer Immunology and Immunotherapy
July 28-30, 2016 Melborne, Australia
World Vaccine Congress 29-31 March 2016, USA
9th vaccine and ISV congress 18-20 Oct 2015 Seoul, South Korea
World Vaccine Congress Asia 2016 Singapore
Annual Conference on Vaccine Research April 18-20 2016 Baltimore USA
Relevant Associations and Societies
This page will be updated regularly.
This page was last updated on December 23, 2024
